ADAT3 Inhibitors
ADAT3 inhibitors encompass a range of compounds that indirectly reduce the functional activity of ADAT3 by influencing the availability and state of its tRNA substrates, rather than directly inhibiting the enzyme itself. These compounds typically disrupt nucleotide metabolism or RNA processing pathways, leading to a reduction in the pool of tRNA substrates or alterations in the tRNA modification patterns that are essential for ADAT3 activity. For example, inhibitors like 5-Iodotubercidin and hydroxyurea reduce the availability of nucleotides necessary for proper tRNA synthesis and modification, thereby indirectly inhibiting the action of ADAT3. Compounds such as 2'-Deoxyadenosine and puromycin may compete with or mimic tRNA components, potentially preventing ADAT3 from accessing its normal substrate.
The indirect inhibition mechanisms also extend to compounds that affect DNA and RNA methyltransferase activities, such as decitabine and azacitidine, which can lead to changes in the RNA modification landscape, thereby indirectly affecting ADAT3's function in tRNA deamination. Other nucleoside analogs like cladribine and ribavirin disrupt the balance of nucleotide pools, which is crucial for the maintenance of tRNA substrate levels and, consequently, for the deamination reactions mediated by ADAT3. Methotrexate and clofarabine demonstrate the broader impact of nucleotide synthesis inhibition on the availability of tRNA substrates for enzymes like ADAT3, highlighting the interconnectedness of metabolic pathways and the indirect mechanisms through which ADAT3 activity can be modulated.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $150.00 $455.00 | 20 | |
A potent adenosine kinase inhibitor that raises intracellular adenosine levels. Elevated adenosine may compete with the normal substrates of ADAT3, thereby reducing the enzyme's ability to deaminate adenosine in tRNA molecules. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A non-selective protein kinase inhibitor that can disrupt multiple signaling pathways. By inhibiting kinases that phosphorylate proteins involved in tRNA synthesis and processing, it may indirectly reduce the availability of ADAT3 substrates. | ||||||
2′-Deoxyadenosine monohydrate | 16373-93-6 | sc-216290 sc-216290A | 250 mg 1 g | $31.00 $46.00 | 2 | |
An adenosine analog that gets incorporated into DNA but can also affect RNA processing. It may compete with adenosine in tRNA, potentially inhibiting ADAT3-mediated deamination. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
An inhibitor of ribonucleotide reductase that decreases the deoxynucleotide pool, potentially altering RNA synthesis and indirectly impairing ADAT3 function due to a reduction in tRNA substrate levels. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
A DNA methyltransferase inhibitor that indirectly influences RNA processing and modification pathways, potentially affecting ADAT3 by disrupting tRNA methylation patterns. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Another DNA methyltransferase inhibitor that can influence global methylation patterns, potentially altering RNA modification processes and indirectly inhibiting ADAT3 activity. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Mimics the 3'-end of aminoacyl-tRNA and causes premature termination of translation, potentially reducing the pool of functional tRNA substrates for ADAT3. | ||||||
2-Chloro-2′-deoxyadenosine | 4291-63-8 | sc-202399 | 10 mg | $144.00 | 1 | |
A nucleoside analog that affects adenosine metabolism and could indirectly reduce ADAT3 activity by disrupting the balance of nucleotide pools. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $62.00 $108.00 $210.00 | 1 | |
An antiviral nucleoside analog that can interfere with nucleotide synthesis and potentially reduce the availability of adenosine for ADAT3-mediated tRNA deamination. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
An inhibitor of dihydrofolate reductase that affects nucleotide synthesis and could indirectly inhibit ADAT3 by reducing the availability of substrates for tRNA modification. | ||||||